 Patients under consideration for lung transplantation as treatment for end-stage lung diseases such as idiopathic pulmonary<disease> fibrosis<disease> ( IPF) often have risk factors such as a history of smoking or concomitant emphysema , both of which can predispose the patient to lung cancer. In fact , IPF itself increases the risk of lung cancer development by 6.8 % to 20 %. Solid organ malignancy ( non-skin) is an established contraindication for lung transplantation. We encountered a clinical dilemma in a patient who presented with an IPF flare-up and underwent urgent evaluation for lung transplantation. After transplant , the patient 's explanted lungs showed extensive adenocarcinoma